Clinical Trials
50
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (50 trials with phase data)• Click on a phase to view related trials
Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: ICP-B794
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 410
- Registration Number
- NCT07136558
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Interventions
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT07082686
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing Municipality, China
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis (MS) Primary Progressive
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 705
- Registration Number
- NCT07067463
ICP-332 in Subjects With Non-segmental Vitiligo
- Conditions
- Non Segmental Vitiligo
- Interventions
- Drug: ICP-332 TabletsDrug: ICP-332 Placebo Tablets
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 603
- Registration Number
- NCT07047612
- Locations
- 🇨🇳
The Second Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Beijing Chao-yang Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Tongren Hospital, Beijing, Beijing, China
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Relapsed or Refractory Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT06845241
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fu zhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hosptital, Zhengzhou, Henan, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next